AbbVie Inc (ABBV)vsEnhabit Inc. (EHAB)
ABBV
AbbVie Inc
$207.86
+2.51%
HEALTHCARE · Cap: $358.55B
EHAB
Enhabit Inc.
$13.78
-0.07%
HEALTHCARE · Cap: $706.40M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5826% more annual revenue ($62.82B vs $1.06B). ABBV leads profitability with a 5.8% profit margin vs -0.4%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
EHAB
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$207.86
$39.53 premium
Margin of Safety
+77.5%
Fair Value
$50.06
Current Price
$13.78
$36.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 8667.0% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
4.7% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -0.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : EHAB
The strongest argument for EHAB centers on Price/Book, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : EHAB
The primary concerns for EHAB are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while EHAB is a turnaround play — different risk/reward profiles.
EHAB carries more volatility with a beta of 0.96 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100) and 12.4% revenue growth. EHAB offers better value entry with a 77.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Enhabit Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Enhabit, Inc. provides home health and hospice services in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?